Company: MIRA
Filing Date: 2025-06-17
Form Type: PREM14A
Source: 0001641172-25-015340
Chunk: 50

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-06-17
Form: PREM14A
Chunk 50
---
 | the                                                                                      
 MIRA Board’s belief that based on Moore’s valuation, it agreed to a favorable            
 Exchange Ratio for MIRA stockholders, and that the terms of the Merger Agreement include 
 favorable terms to MIRA.                                                                 |

The MIRA Board also reviewed various reasons impacting the financial condition, results of operations and prospects of SKNY, including:

| ● | the                                                                                    
 risks associated with entering a new product market for SKNY-1 in an area where MIRA’s 
 senior management does not have prior expertise;                                       |

| ● | the                                                                                               
 risks associated with SKNY-1 becoming a commercially viable program, the competitive landscape    
 among pharmaceutical products designed to address obesity and smoking, and the inherent technical 
 risks of early-stage pharmaceutical programs;                                                     |

| ● | the                                                                                                 
 risks associated with early preclinical assets and the timelines for beginning clinical development 
 and demonstrating clinical proof-of-concept.                                                        |

| ● | the                                                                                        
 risks associated with the conflicts of interest involved in the Merger, including that the 
 terms of the Merger primarily address the interests of SKNY and MIRAs’ management and      
 related parties at the expense of MIRA’s shareholders.                                     |

The MIRA Board also reviewed the terms and conditions of the Merger Agreement, as well as the safeguards and protective provisions included therein intended to mitigate risks, including:

| ● | the                                                                                          
 initial estimated Exchange Ratio used to establish the number of shares of MIRA Common Stock 
 to be issued to SKNY’s stockholders in the Merger was determined based on the relative       
 valuations of MIRA and SKNY as is described in the Moore valuation study;                    |

| ● | the                                                                                          
 limited number and nature of the conditions to SKNY’s obligation to consummate the           
 Merger and the limited risk of non-satisfaction of such conditions as well as the likelihood 
 that the Merger will be consummated on a timely basis;                                       |

| ● | the                                                                                  
 agreement of SKNY to provide the written consent of SKNY’s stockholders necessary to 
 adopt the Merger Agreement and the actual receipt of such written consent; and       |

| ● | the                                                                                          
 belief that the terms of the Merger Agreement, including the parties’ representations,       
 warranties and covenants, and the conditions to their respective obligations, are reasonable 
 under the circumstances.                                                                     |

| 25 |

In the course of its deliberations, the MIRA Board also considered a variety of risks and other countervailing